CD274 and non-small cell lung carcinoma: In November 2024, Roche published interim results from the next SKYSCRAPER-01 study, a global, double-blind, phase III study evaluating tiragolumab plus Tecentriq versus Tecentriq alone in patients with PD-L1-high previously untreated, locally advanced, unresectable or metastatic non-small-cell lung cancer (NSCLC).